Streetbeat News

Analyst Ratings

RNA

Cantor Fitzgerald analyst Eric Schmidt has reiterated an Overweight rating on Avidity Biosciences (NASDAQ:RNA) and maintained a price target of $96.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 1:20 pm

FERG

UBS analyst John Lovallo maintains a Buy rating on Ferguson Enterprises and raises the price target from $228 to $236.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 1:19 pm

CLDX

Cantor Fitzgerald has reiterated its Overweight rating on Celldex Therapeutics, maintaining a price target of $67.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 1:18 pm

ET

UBS analyst Shneur Gershuni has maintained a Buy rating on Energy Transfer (NYSE:ET) and raised the price target from $22 to $23.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 1:17 pm

RMD

ResMed shares declined following a downgrade by Wolfe Research from Peer Perform to Underperform, with a new price target of $180.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 1:16 pm

LANC

Benchmark analyst Todd Brooks has reiterated a Hold rating on Lancaster Colony (NASDAQ:LANC).

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 1:15 pm

FARM

Roth MKM analyst Gerry Sweeney maintains a Buy rating on Farmer Bros (NASDAQ:FARM) but lowers the price target from $6 to $4.5.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 1:15 pm

BNTX

UBS analyst Eliana Merle maintains a Neutral rating on BioNTech (NASDAQ:BNTX) but raises the price target from $97 to $131.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 1:14 pm

HITI

Roth MKM analyst Scott Fortune has reiterated a Buy rating on High Tide (NASDAQ:HITI) and maintained a price target of $4.5.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 1:13 pm

BAK

UBS analyst Luiz Carvalho has upgraded Braskem (NYSE:BAK) from Neutral to Buy, raising the price target from $7.7 to $10.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 1:11 pm